Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT trial in decompensated cirrhosis
2023-507073-18-00Phase 2Authorised
- Sponsor
- European Foundation for the Study of Chronic Liver Failure
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, single-arm trial of albumin (human) and enoxaparin in Cirrhosis, sponsored by European Foundation for the Study of Chronic Liver Failure. Primary endpoints: Treatment-emergent adverse events or serious adverse events and Drug discontinuation due to key safety events. Planned start Dec 2023; status: authorised.
02
Drugs
albumin (human)enoxaparin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2023-507073-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507073-18-00.